Core Insights - Thermo Fisher is close to an all-cash acquisition of Clario, a drug trial software company, with a potential valuation of around $10 billion [1] Company Summary - The acquisition reflects Thermo Fisher's strategy to enhance its capabilities in the healthcare technology sector [1] - Clario specializes in software solutions for drug trials, indicating a focus on improving clinical research processes [1] Industry Summary - The deal highlights ongoing consolidation in the healthcare technology industry, particularly in sectors related to drug development and clinical trials [1] - The valuation of approximately $10 billion underscores the significant investment interest in technology that supports healthcare and pharmaceutical advancements [1]